Bruton's tyrosine kinase regulates TLR9 but not TLR7 signaling in human plasmacytoid dendritic cells

European Journal of Immunology

Volumn 44, Issue 4, 2014, Pages 1130-1136

  Wang, Jingming ^a   Lau, Kai Yeung ^a   Jung, Jimmy ^a   Ravindran, Palanikumar ^a   Barrat, Franck J ^a  

^a HOFFMANN LA ROCHE INC   (United States)

Author keywords

Autoimmunity; Bruton's tyrosine kinase; Innate immunity; Plasmacytoid dendritic cells; Toll like receptors

Indexed keywords

ALPHA INTERFERON; BRUTON TYROSINE KINASE; BRUTON TYROSINE KINASE INHIBITOR; CD40 ANTIGEN; CD69 ANTIGEN; CD86 ANTIGEN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON REGULATORY FACTOR 7; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; RN 486; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ARTICLE; CELL MATURATION; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DOWN REGULATION; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; IC 50; IFI44L GENE; IFIT1 GENE; IFITM1 GENE; IMMUNE RESPONSE; IRF GENE; ISG15 GENE; MX1 GENE; MX2 GENE; NORMAL HUMAN; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UPREGULATION;

AUTOIMMUNITY; BRUTON'S TYROSINE KINASE; INNATE IMMUNITY; PLASMACYTOID DENDRITIC CELLS; TOLL-LIKE RECEPTORS;

CELLS, CULTURED; CHEMOKINE CCL4; CHEMOKINE CXCL10; DENDRITIC CELLS; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; HUMANS; INTERFERON REGULATORY FACTOR-7; INTERFERON-ALPHA; ISOQUINOLINES; NF-KAPPA B; OLIGODEOXYRIBONUCLEOTIDES; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 7; TOLL-LIKE RECEPTOR 9; TRANSCRIPTOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84897978425     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201344030     Document Type: Article

References (24)

1. Reizis, B., Bunin, A., Ghosh, H. S., Lewis, K. L. and Sisirak, V., Plasmacytoid dendritic cells: recent progress and open questions. Annu. Rev. Immunol. 2011. 29: 163-183.
2. Kanzler, H., Barrat, F. J., Hessel, E. M. and Coffman, R. L., Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat. Med. 2007. 13: 552-559.
3. Hooks, J. J., Moutsopoulos, H. M., Geis, S. A., Stahl, N. I., Decker, J. L. and Notkins, A. L., Immune interferon in the circulation of patients with autoimmune disease. N. Engl. J. Med. 1979. 301: 5-8.
4. Banchereau, J. and Pascual, V., Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity 2006. 25: 383-392.
5. Chaussabel, D., Quinn, C., Shen, J., Patel, P., Glaser, C., Baldwin, N., Stichweh, D. et al., A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus. Immunity 2008. 29: 150-164.
6. Guiducci, C., Gong, M., Xu, Z., Gill, M., Chaussabel, D., Meeker, T., Chan, J. H. et al., TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus. Nature 2010. 465: 937-941.
7. Barrat, F. J., Meeker, T., Gregorio, J., Chan, J. H., Uematsu, S., Akira, S., Chang, B. et al., Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J. Exp. Med. 2005. 202: 1131-1139.
8. Means, T. K., Latz, E., Hayashi, F., Murali, M. R., Golenbock, D. T. and Luster, A. D., Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J. Clin. Invest 2005. 115: 407-417.
9. Garcia-Romo, G. S., Caielli, S., Vega, B., Connolly, J., Allantaz, F., Xu, Z., Punaro, M. et al., Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci. Transl. Med. 2011. 3: 73ra20.
10. Lande, R., Ganguly, D., Facchinetti, V., Frasca, L., Conrad, C., Gregorio, J., Meller, S. et al., Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus. Sci. Transl. Med. 2011. 3: 73ra19.
11. Kumar, H., Kawai, T. and Akira, S., Pathogen recognition by the innate immune system. Int. Rev. Immunol. 2011. 30: 16-34.
12. Chang, B. Y., Huang, M. M., Francesco, M., Chen, J., Sokolove, J., Magadala, P., Robinson, W. H. et al., The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells. Arthritis Res. Ther. 2011. 13: R115.
13. Di Paolo, J. A., Huang, T., Balazs, M., Barbosa, J., Barck, K. H., Bravo, B. J., Carano, R. A. et al., Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis. Nat. Chem. Biol. 2011. 7: 41-50.
14. Horwood, N. J., Page, T. H., McDaid, J. P., Palmer, C. D., Campbell, J., Mahon, T., Brennan, F. M. et al., Bruton's tyrosine kinase is required for TLR2 and TLR4-induced TNF, but not IL-6, production. J. Immunol. 2006. 176: 3635-3641.
15. Doyle, S. L., Jefferies, C. A., Feighery, C. and O'Neill, L. A., Signaling by Toll-like receptors 8 and 9 requires Bruton's tyrosine kinase. J. Biol. Chem. 2007. 282: 36953-36960.
16. Honigberg, L. A., Smith, A. M., Sirisawad, M., Verner, E., Loury, D., Chang, B., Li, S. et al., The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc. Natl. Acad. Sci. USA 2010. 107: 13075-13080.
17. Xu, D., Kim, Y., Postelnek, J., Vu, M. D., Hu, D. Q., Liao, C., Bradshaw, M. et al., RN486, a selective Bruton's tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents. J. Pharmacol. Exp. Ther. 2012. 341: 90-103.
18. Guiducci, C., Ott, G., Chan, J. H., Damon, E., Calacsan, C., Matray, T., Lee, K. D. et al., Properties regulating the nature of the plasmacytoid dendritic cell response to Toll-like receptor 9 activation. J. Exp. Med. 2006. 203: 1999-2008.
19. Soumelis, V. and Liu, Y. J., From plasmacytoid to dendritic cell: morphological and functional switches during plasmacytoid pre-dendritic cell differentiation. Eur. J. Immunol. 2006. 36: 2286-2292.
20. Sancho, D., Gomez, M. and Sanchez-Madrid, F., CD69 is an immunoregulatory molecule induced following activation. Trends Immunol. 2005. 26: 136-140.
21. Guiducci, C., Ghirelli, C., Marloie-Provost, M. A., Matray, T., Coffman, R. L., Liu, Y. J., Barrat, F. J. et al., PI3K is critical for the nuclear translocation of IRF-7 and type I IFN production by human plasmacytoid predendritic cells in response to TLR activation. J. Exp. Med. 2008. 205: 315-322.
22. Barrat, F. J. and Coffman, R. L., Development of TLR inhibitors for the treatment of autoimmune diseases. Immunol. Rev. 2008. 223: 271-283.
23. Christensen, S. R., Shupe, J., Nickerson, K., Kashgarian, M., Flavell, R. A. and Shlomchik, M. J., Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity 2006. 25: 417-428.
24. Nickerson, K. M., Christensen, S. R., Shupe, J., Kashgarian, M., Kim, D., Elkon, K. and Shlomchik, M. J., TLR9 regulates TLR7- and MyD88-dependent autoantibody production and disease in a murine model of lupus. J. Immunol. 2010. 184: 1840-1848.